Cordlife

Leading Cord Blood Banking company Cordlife Ltd (ASX: CBB) today announced that it plans to introduce new shareholders to its wholly owned Cytomatrix Group, which holds its patented cell expansion (Transtem) and T-cell production (Regenimmune) technologies.

Leading healthcare company CyGenics Ltd (ASX: CYN) today announced that it had been awarded the prestigious Technology Pioneer status by the Geneva-based World Economic Forum for advancing the field of adult stem cell cellular therapy, cord blood banking and technologies.

Leading heathcare company CyGenics Ltd (ASX: CYN) today signed an agreement with the Blood Centre of Zhejiang Province (ZBC) in China for development work generating human T cells outside the body for the treatment of HIV, using CyGenics' proprietary cellular growth technology.

Leading Indonesian pharmaceutical company, Kalbe Farma and CyGenics (ASX: CYN) Officially launch their cord blood bank in Indonesia.

Leading tissue and cord blood banking company CyGenics Ltd. (ASX: CYN) today announced Indonesia's leading pharma company, Kalbe Farma, has taken a 49% stake in its cord blood banking subsidiary, CordLife Indonesia.

Leading tissue and cord blood banking company CyGenics Ltd. (ASX: CYN) today announced that it will focus primarily on its core revenue-generating tissue and cord blood banking businesses, which continue to show substantial growth in both numbers of clients and revenue.

CyGenics Ltd. (ASX: CYN) today formally completed its strategic investment of an initial 20% stake in Dutch-based Pharmacell BV, with an option to purchase the remaining 80% at a later date.

Cygenics (ASX: CYN) announce the first cystic fibrosis cord blood collection. Clinical history was made at The Mercy Hospital in Werribee on Easter Saturday, when baby Aiden Brundell donated his cord blood in the hope that his precious stem cells could one day rejuvenate sister Mikaela's lungs, which are failing from cystic fibrosis (CF), and save her life.

CyGenics Ltd. (ASX: CYN) announced its plans to establish a sound base in the European market to take advantage of exciting business opportunities in those markets. As a first step, CyGenics plans to acquire a significant stake in Dutch-based PharmaCell BV.

Leading cell therapy services company CyGenics Ltd. (ASX: CYN) announced that its US-based subsidiary, Cytomatrix LLC, had been granted US Patent 6991933, Cell Culture Spinner Flasks. This patent adds to the five already granted to the CyGenics group. A number of other patents are pending.